
1. sci rep. 2016 jun 13;6:27806. doi: 10.1038/srep27806.

comparative chemical genomics reveal spiroindolone antimalarial kae609
(cipargamin) p-type atpase inhibitor.

goldgof gm(1)(2), durrant jd(3), ottilie s(1), vigil e(1), allen ke(4), gunawan
f(1), kostylev m(2), henderson ka(5), yang j(1), schenken j(1), lamonte gm(1),
manary mj(1), murao a(2), nachon m(1), stanhope r(1), prescott m(1), mcnamara
cw(6), slayman cw(4), amaro re(3), suzuki y(2), winzeler ea(1).

author information: 
(1)division pharmacology drug discovery, department pediatrics,
university california, san diego, school medicine, la jolla, california,
usa.
(2)department synthetic biology bioenergy, j. craig venter institute, la
jolla, california, usa.
(3)department chemistry &biochemistry national biomedical computation 
resource, university california, san diego, la jolla, california, usa.
(4)department genetics, yale university school medicine, new haven,
connecticut, usa.
(5)basic sciences division, fred hutchinson cancer research center, seattle, wa, 
usa.
(6)genomics institute novartis research foundation, san diego, california,
usa.

the spiroindolones, new class antimalarial medicines discovered a
cellular screen, rendered less active mutations parasite p-type
atpase, pfatp4. show s. cerevisiae also acquires mutations gene
encoding p-type atpase (scpma1) exposure spiroindolones these
mutations sufficient resistance. kae609 resistance mutations scpma1 do
not confer resistance unrelated antimicrobials, confer cross
sensitivity alkyl-lysophospholipid edelfosine, known displace 
scpma1p plasma membrane. using vitro cell-free assay, we
demonstrate kae609 directly inhibits scpma1p atpase activity. kae609 also
increases cytoplasmic hydrogen ion concentrations yeast cells. computer
docking scpma1p homology model identifies binding mode supports
genetic resistance determinants vitro experimental structure-activity
relationships p. falciparum s. cerevisiae. model also suggests a
shared binding site dihydroisoquinolones antimalarials. data support
a model kae609 exerts antimalarial activity directly interfering 
with p-type atpase activity.

doi: 10.1038/srep27806 
pmcid: pmc4904242
pmid: 27291296  [indexed medline]

